Browse WFDC2

Summary
SymbolWFDC2
NameWAP four-disulfide core domain 2
Aliases HE4; WAP5; dJ461P17.6; EDDM4; epididymal protein 4; WAP domain containing protein HE4-V4; epididymal secreto ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF00095 WAP-type (Whey Acidic Protein) 'four-disulfide core'
Function

Broad range protease inhibitor.

> Gene Ontology
 
Biological Process GO:0007283 spermatogenesis
GO:0010466 negative regulation of peptidase activity
GO:0010951 negative regulation of endopeptidase activity
GO:0045861 negative regulation of proteolysis
GO:0048232 male gamete generation
GO:0051346 negative regulation of hydrolase activity
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004866 endopeptidase inhibitor activity
GO:0004867 serine-type endopeptidase inhibitor activity
GO:0004869 cysteine-type endopeptidase inhibitor activity
GO:0019828 aspartic-type endopeptidase inhibitor activity
GO:0030414 peptidase inhibitor activity
GO:0061134 peptidase regulator activity
GO:0061135 endopeptidase regulator activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolWFDC2
NameWAP four-disulfide core domain 2
Aliases HE4; WAP5; dJ461P17.6; EDDM4; epididymal protein 4; WAP domain containing protein HE4-V4; epididymal secreto ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between WFDC2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between WFDC2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24886523Ovarian CarcinomaInhibit immunityHowever, CA125 continues to be, with the recent exception of HE4, the only clinically reliable diagnostic marker for ovarian cancer.
29745428Ovarian CarcinomaInhibit immunityHE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells. SKOV3 and OVCAR8, human ovarian carcinoma cell lines, exhibited enhanced proliferation in conditioned media from HE4-exposed PBMCs, an effect that was attenuated by the addition of recombinant OPN or OPN-inducible cytokines (IL-12 and IFN-γ).
Summary
SymbolWFDC2
NameWAP four-disulfide core domain 2
Aliases HE4; WAP5; dJ461P17.6; EDDM4; epididymal protein 4; WAP domain containing protein HE4-V4; epididymal secreto ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of WFDC2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolWFDC2
NameWAP four-disulfide core domain 2
Aliases HE4; WAP5; dJ461P17.6; EDDM4; epididymal protein 4; WAP domain containing protein HE4-V4; epididymal secreto ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of WFDC2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4020.611
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.0490.102
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.7750.54
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.6990.0491
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.9760.59
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472.610.224
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0430.962
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1960.889
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2390.877
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.5130.822
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-3.1170.389
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0460.869
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of WFDC2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolWFDC2
NameWAP four-disulfide core domain 2
Aliases HE4; WAP5; dJ461P17.6; EDDM4; epididymal protein 4; WAP domain containing protein HE4-V4; epididymal secreto ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of WFDC2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolWFDC2
NameWAP four-disulfide core domain 2
Aliases HE4; WAP5; dJ461P17.6; EDDM4; epididymal protein 4; WAP domain containing protein HE4-V4; epididymal secreto ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of WFDC2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by WFDC2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolWFDC2
NameWAP four-disulfide core domain 2
Aliases HE4; WAP5; dJ461P17.6; EDDM4; epididymal protein 4; WAP domain containing protein HE4-V4; epididymal secreto ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of WFDC2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolWFDC2
NameWAP four-disulfide core domain 2
Aliases HE4; WAP5; dJ461P17.6; EDDM4; epididymal protein 4; WAP domain containing protein HE4-V4; epididymal secreto ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of WFDC2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolWFDC2
NameWAP four-disulfide core domain 2
Aliases HE4; WAP5; dJ461P17.6; EDDM4; epididymal protein 4; WAP domain containing protein HE4-V4; epididymal secreto ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between WFDC2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolWFDC2
NameWAP four-disulfide core domain 2
Aliases HE4; WAP5; dJ461P17.6; EDDM4; epididymal protein 4; WAP domain containing protein HE4-V4; epididymal secreto ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting WFDC2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.